Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Prospective randomized open multicenter trial with blinded adjudication of endpoints to
assess the efficacy of six-month low-dose LMWH (Low Molecular Weight Heparin) for the
prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and
elevated D-dimer.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Ministry of Health, France National Cancer Institute, France